Andrew J. Last's Insider Trades & SAST Disclosures
Andrew J. Last's most recent trade in Bio-Rad Laboratories Inc. - Ordinary Shares - Class A was a trade of 3,000 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Sept. 6, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Andrew J. Last.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2024 | 3,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 329.94 per share. | 06 Sep 2024 | 3,000 | 7,559 (0%) | 0% | 329.9 | 989,815 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 299.24 per share. | 06 Sep 2024 | 3,000 | 10,559 (0%) | 0% | 299.2 | 897,720 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,252 | 3,756 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,252 | 7,010 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 903 | 0 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 903 | 8,017 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 867 | 1,735 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 867 | 7,242 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 337.32 per share. | 01 Sep 2024 | 635 | 6,375 (0%) | 0% | 337.3 | 214,198 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 633 | 633 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 633 | 7,435 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 337.32 per share. | 01 Sep 2024 | 458 | 7,559 (0%) | 0% | 337.3 | 154,493 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 337.32 per share. | 01 Sep 2024 | 440 | 6,802 (0%) | 0% | 337.3 | 148,421 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 337.32 per share. | 01 Sep 2024 | 321 | 7,114 (0%) | 0% | 337.3 | 108,280 | Bio-Rad A Common Stock |
| Oncocyte Corporation | Andrew J. Last | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 30,000 | 30,000 | - | - | Option to Purchase Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2024 | 1,000 | 0 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2024 | 1,000 | 6,076 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 277.11 per share. | 29 Apr 2024 | 357 | 5,719 (0%) | 0% | 277.1 | 98,928 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 5,891 | 5,891 | - | - | Non-Qualified Stock Option (right to buy) | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2023 | 5,008 | 5,008 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 903 | 5,487 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 903 | 903 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 867 | 4,660 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 867 | 2,602 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 633 | 4,863 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 633 | 1,266 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 394.60 per share. | 01 Sep 2023 | 448 | 5,039 (0%) | 0% | 394.6 | 176,781 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 394.60 per share. | 01 Sep 2023 | 430 | 4,230 (0%) | 0% | 394.6 | 169,678 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 394.60 per share. | 01 Sep 2023 | 279 | 4,584 (0%) | 0% | 394.6 | 110,093 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2023 | 1,000 | 4,112 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2023 | 1,000 | 1,000 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 450.79 per share. | 29 Apr 2023 | 346 | 3,766 (0%) | 0% | 450.8 | 155,973 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2022 | 902 | 1,806 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2022 | 902 | 3,531 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 478.32 per share. | 02 Sep 2022 | 448 | 3,083 (0%) | 0% | 478.3 | 214,287 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 3,469 | 3,469 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 633 | 2,943 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 633 | 1,899 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 486.25 per share. | 01 Sep 2022 | 314 | 2,629 (0%) | 0% | 486.3 | 152,683 | Bio-Rad A Common Stock |
| Oncocyte Corporation | Andrew J. Last | Director | Purchase of securities on an exchange or from another person at price $ 0.87 per share. | 17 Aug 2022 | 20,000 | 70,170 (0%) | 0% | 0.9 | 17,400 | Common Stock, no par value |
| Oncocyte Corporation | Andrew J. Last | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 45,000 | 45,000 | - | - | Option to Purchase Common Stock | |
| Oncocyte Corporation | Andrew J. Last | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 10,000 | 50,170 (0%) | 0% | 0 | Common Stock, no par value | |
| Oncocyte Corporation | Andrew J. Last | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2022 | 10,000 | 40,170 (0%) | 0% | 0 | Common Stock, no par value | |
| Oncocyte Corporation | Andrew J. Last | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2022 | 10,000 | 0 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2022 | 1,000 | 2,764 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2022 | 1,000 | 2,000 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 512.06 per share. | 29 Apr 2022 | 471 | 2,293 (0%) | 0% | 512.1 | 241,180 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 2,532 | 2,532 | - | - | Non-Qualified Stock Option (right to buy) | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 2,532 | 2,532 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 299.24 per share. | 01 Sep 2021 | 2,000 | 3,281 (0%) | 0% | 299.2 | 598,480 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 2,000 | 3,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 902 | 2,183 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 902 | 2,708 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 812.27 per share. | 01 Sep 2021 | 750 | 2,531 (0%) | 0% | 812.3 | 609,203 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 813.15 per share. | 01 Sep 2021 | 651 | 1,880 (0%) | 0% | 813.2 | 529,361 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 814.09 per share. | 01 Sep 2021 | 599 | 1,281 (0%) | 0% | 814.1 | 487,640 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 825.77 per share. | 01 Sep 2021 | 448 | 1,735 (0%) | 0% | 825.8 | 369,945 | Bio-Rad A Common Stock |
| Oncocyte Corporation | Andrew J. Last | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 45,000 | 45,000 | - | - | Option to Purchase Common Stock | |
| Oncocyte Corporation | Andrew J. Last | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Oncocyte Corporation | Andrew J. Last | Director | 11 Jun 2021 | 6,993 | 0 | - | - | Warrants | ||
| Oncocyte Corporation | Andrew J. Last | Director | 11 Jun 2021 | 6,993 | 30,170 (0%) | 0% | 3 | 20,979 | Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 1,000 | 3,000 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 1,000 | 1,733 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 640.73 per share. | 29 Apr 2021 | 466 | 1,267 (0%) | 0% | 640.7 | 298,580 | Bio-Rad A Common Stock |
| Oncocyte Corporation | Andrew J. Last | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 16,184 | 23,177 (0%) | 0% | - | Common Stock | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2020 | 3,610 | 3,610 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Andrew J. Last | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2020 | 3,610 | 3,610 | - | - | Non-Qualified Stock Option (right to buy) | |
| Oncocyte Corporation | Andrew J. Last | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 57,000 | 57,000 | - | - | Option to purchase common stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges